Navigation Links
Cellular Dynamics International and VivoMedica Launch the CARDIOTOX Consortium to Validate a Human Cardiac Model for Preclinical Cardiotoxicity Testing

MADISON, Wis. and SITTINGBOURNE, Kent, England, Sept. 14 /PRNewswire/ -- Cellular Dynamics International (CDI) and VivoMedica plc announce the launch of CARDIOTOX - a pharmaceutical industry consortium to validate a human cell model and analysis system for preclinical cardiotoxicity testing of pharmaceutical candidate compounds. The consortium will be formally launched at the Safety Pharmacology Society 9th Annual Meeting in Strasbourg, France, on Sept. 15-18, 2009, during a workshop sponsored by CDI and VivoMedica at 12:30p.m. CET on Sept. 17.

Pharmaceutical companies are invited to participate in the consortium, which aims to provide the industry with a human cardiomyocyte-based solution to predict pro-arrhythmic effects of new chemical entities (NCEs). Human cardiomyocytes, or heart cells, express the relevant cardiac proteins and are thought to be more predictive of a drug compound's effect than animal cell-based technologies. The consortium will validate the testing system using CDI's revolutionary iCell(TM) Cardiomyocytes and VivoMedica's DrugPrint(R) analysis system. Extracellular micro-electrode array (MEA) recordings from CDI's fully functional induced pluripotent stem (iPS) cell-derived human cardiomyocytes will be analyzed using VivoMedica's proprietary electrical waveform analysis technology. This approach will identify drug-induced changes that indicate the arrhythmogenic potential of NCEs under investigation. These technologies, combined into an integrated test, will provide the industry with a validated pro-arrhythmia reference database for comprehensive early assessment of NCE's arrhythmogenic potential, the end result being greater predictive power, reduced reliance on animal testing, reduced cost, and an overall increase in efficiency in the drug discovery and development process.

"Adverse cardiac effects have resulted in the withdrawal or blackbox warnings of multiple high profile drugs in recent years. Even now it's estimated that 25-40% of all drugs in pre-clinical testing show some adverse drug-induced cardiotoxicity," said Julian Demmon, CEO of VivoMedica. "The challenge for the industry is how to reliably predict clinical cardiotoxicity earlier in the pipeline and thus to target drug development funding more effectively. We believe that iCell Cardiomyocytes in the DrugPrint system will help the pharmaceutical industry overcome this challenge."

"Maintaining a normal cardiac rhythm requires the complex coordination of dozens of proteins. Disruption of this interplay, even for a few minutes, can have severe consequences and even death," said Craig T. January, M.D., Ph.D., F.A.C.C., director and founder of CDI. "Incorporating human cells into toxicology testing is an important goal in the pharmaceutical industry, as human-based models are more likely to recapitulate relevant in vivo biology."

"Mimicking drug toxicity that would manifest itself in clinical trials is a key component of improving the efficiency of drug development," said Chris Kendrick-Parker, chief commercialization officer of CDI. "We have been able to reliably and consistently generate large numbers of human cardiomyocytes for use in pharmaceutical drug development using our iPS cell technologies. Incorporating iCell Cardiomyocytes into VivoMedica's DrugPrint platform will enable our customers to access a reliable human cardiomyocyte cell model in a highly effective testing system."

More information can be found at

About Cellular Dynamics International, Inc.

Cellular Dynamics International, Inc. (CDI) is a leading developer of next-generation stem cell technologies for drug development and personalized medicine applications. CDI harnesses the power of pluripotent stem cells and their ability to differentiate into any cell type for world-class drug development tools. In addition, it is the leader in iPS technology, the production of pluripotent stem cell lines from adult tissue. CDI was founded in 2004 by Dr. James Thomson, a pioneer in human embryonic stem cell research at the University of Wisconsin-Madison, and Tactics II Ventures, a Wisconsin-based venture capital fund. CDI's facilities are located in Madison, Wisconsin. See

About VivoMedica

VivoMedica plc is a British company that delivers high value technology solutions to the global Pharmaceutical Industry. These specialist Pharma-Ware solutions are designed to improve the cost, efficiency and effectiveness of the complex processes involved in the discovery and development of drugs, and in their effective use in treatment pathways. VivoMedica identifies, licenses and develops technologies that support these crucial process developments, and integrates them into products and service offerings that address the challenging needs of the global healthcare market. VivoMedica's lead programme is developed from a suite of patented healthcare technologies licensed from QinetiQ, and provides innovative solutions in the field of cardiotoxicity testing in drug development (DrugPrint(R)). VivoMedica is based at the Kent Science Park, Sittingbourne, England. See

SOURCE Cellular Dynamics International (CDI)
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Novel Valortim(R) Mechanism of Action Data Presented at the Keystone Symposia on Molecular and Cellular Biology
2. Intra-Cellular Therapies Announces Successful Outcome of a Phase II Clinical Trial with ITI-007 in Patients with Sleep Maintenance Insomnia
3. Light Sciences Oncology Completes Patient Enrollment in Phase 3 Clinical Trial of Litx as a Treatment for Hepatocellular Carcinoma
4. Seahorse Bioscience Announces the XF96 Extracellular Flux Analyzer for Cellular Bioenergetics
5. Novel Photoconductive Life Science Research Innovation Enables Rapid, Reproducible, and Non-Invasive Cellular Excitation
6. Molecular Discoveries Shed Light on Liver Cancer -- Hepatocellular Carcinoma (HCC)
7. Intra-Cellular Therapies Announces the Discovery of Potent Antidepressant Activity in ITI-007
8. Intra-Cellular Therapies Announces the Discovery of Potent Antidepressant Activity in ITI-007/ITI-722
9. Pre-Clinical Data Show Intracellular Pathways Affected by ONCONASE(R)
10. Intra-Cellular Therapies Presents Data on Its Schizophrenia and Cognition in Schizophrenia Programs at the 14th Biennial Winter Workshop on Schizophrenia and Bipolar Disorders
11. Intra-Cellular Therapies Initiates Phase 2 Clinical Trial for Sleep Maintenance Insomnia
Post Your Comments:
(Date:11/30/2015)... , Nov. 30, 2015   Royal Philips ... Implant, the industry,s first MRI guided user interface and ... of patients with MR Conditional implants, such as knee ... 2015 Radiological Society of North America Annual Meeting ... and supports diagnostic confidence of this growing patient population. ...
(Date:11/30/2015)... BOCA RATON, Fla. , Nov. 30, ... of Public Research (the Institute) announced today that ... , a medical device start-up company with technology developed ... creation based on publicly-funded research, and bridges early funding ... -based universities and research institutions. ...
(Date:11/30/2015)... Nov. 30, 2015 Baxalta Incorporated ... leader dedicated to delivering transformative therapies to ... conditions, today announced the launch and first ... an extended circulating half-life recombinant factor VIII ... full-length ADVATE [Antihemophilic Factor (Recombinant)]. The treatment ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... November 30, 2015 , ... ... Centers’ National Poison Data System (NPDS) reveals that in 2014, someone called a ... cases, over two million of which were human exposure cases. , The American ...
(Date:11/30/2015)... ... November 30, 2015 , ... Brenntag Specialties, Inc. ... partner for the Nutraceutical Specialties products into oral solid dosage in the over ... , “We are pleased to announce our expanded distribution agreement with ASI.” said ...
(Date:11/30/2015)... ... November 30, 2015 , ... ... announced at the Radiology Society of North America (RSNA) annual meeting, being held ... 60% growth from 2014. Throughout 2015, the company has completed installations for ...
(Date:11/30/2015)... ... November 30, 2015 , ... Holcomb – Kreithen Plastic ... surgery practices in Florida, is proud to announce that Dr. Joshua Kreithen, one ... Ethicon Inc., a Johnson & Johnson Company. , Ethicon is a global medical ...
(Date:11/30/2015)... (PRWEB) , ... November 30, 2015 , ... ... strategic alliance around Novus’ TIGR® Matrix Surgical Mesh technology for soft tissue repair ... polymers, TIGR® Matrix is a long-term resorbable surgical mesh intended to support and ...
Breaking Medicine News(10 mins):